Effect of phosphatidylcholine on lymphatic drainage and fluid loss from the peritoneal cavity of sheep. The purpose of this investigation was to test the hypothesis that phosphatidyicholine enhances net ultrafiltration by decreasing lymphatic drainage of the peritoneal cavity. Twelve sheep were used in this study. Six animals received 50 mI/kg intraperitoneal infusions of Dianeal5 4.25% (490 mOsm/liter) and six received similar volumes of premixed phosphatidylcholine-Dianeal® (510 mOsm/liter). Labeled albumin (25 Ci '251-human serum albumin) was added to the dialysate as a lymph flow marker. Lymph drainage of the peritoneal cavity was estimated from the appearance of the intraperitoneally administered tracer in the blood. Net ultrafiltration was significantly enhanced by phosphatidylcholine at each hour up to 6 hours post-infusion, and over this period reached 30.3 3.8 mI/kg in the phosphatidyicholine animals compared to 12.2 2.
transcapillary transport of water and solutes [8] or inhibits pentoneal lymphatic drainage [5, 9] .
In this report we investigated the effects of phosphatidyicholine on lymphatic drainage of the peritoneal cavity in sheep. Lymph drainage pathways and measurements of lymph flow from the peritoneal cavity in this species have been studied extensively [10] [11] [12] [13] [14] [15] . We provide evidence that phosphatidyicholine enhanced net ultrafiltration. While phosphatidyicholine depressed lymphatic drainage, it appeared to exert its effect on peritoneal volumes largely by increasing the capillary transport of fluid into the peritoneal cavity.
Methods

Solutions and tracer
Radiolabeled albumin ('25I-human serum albumin solution 2.5 pCi/mg, 10 mg) was used as the lymph flow marker. This tracer was purchased from Frosst (Kirkland, Quebec, Canada). The premixed phosphatidyicholine-Dianeal® solution was provided by Baxter R&D Europe, Nivelles, Belgium. This solution is a slightly cloudy emulsion with 75% of the emulsion particles below 1 and 25% between 1 and 2 .t (510 mOsm/liter [7] ). Dianeal® 4.25% (purchased from Baxter Healthcare, Deerfield Illinois, USA) served as control (480 to 490 mOsm/liter, measured in our laboratory).
Animals
Twelve randomly bred female sheep (approximately 6 months old) ranging in weight from 24 to 31 kg were used in this investigation.
Anesthesia and surgery
Pentothal sodium (Boehriger Ingelheim, Burlington, Ontario, Canada) was given intravenously (15 to 25 mg/kg body wt) to induce anesthesia. The sheep were then intubated with a Sheridan/HVT tracheal tube (Sheridan Catheter Corp., Argyle, New York, USA). Surgical and post-operative anesthesia were maintained with 1 to 2% fluothane (Halothane, Ayerst Laboratories, New York City, New York, USA) in oxygen using a respiration pump (Ventimeter Ventilater, Air Shields Inc., Hatboro, Pennsylvania, USA).
A small right lateral incision was made approximately 10 to 12 cm posterior to the last rib through which a Tenchkoff peritoneal dialysis catheter equipped with two Dacron cuffs (Accurate Surgical Instruments Corp., Toronto, Ontaio, Canada) was inserted and the wound closed with suture silk. A catheter was placed in the right external jugular vein for sequential blood sampling. The animals were allowed to recover for 24 hours in a metabolism cage.
Experimental protocol
Prewarmed (37°C) phosphatidylcholine-DianeaU or Dianeal® solution containing 25 Ci of '251-albumin was infused into the peritoneal cavity at t = 0 hours. Hourly samples of peritoneal dialysate fluid (5 ml) and blood (10 ml) were taken via the peritoneal catheter and the intravenous jugular catheter respectively for a period of six hours. At the end of each experiment (t = 6 hours), the animals were sacrificed and any remaining fluid in the peritoneal cavity was allowed to drain by gravity via the peritoneal catheter into a graduated cylinder. This volume was measured and three 10 ml samples were taken. Since there would be an unknown volume of fluid remaining in the peritoneal cavity, an additional 1,000 ml of saline was instilled. The cavity was then opened and the contents thoroughly massaged to ensure that any 1251-albumin was mixed well with the added saline. An additional three 10 ml samples were taken from three different regions of the peritoneal cavity.
Each of the blood and peritoneal lavage samples was centrifuged for 15 minutes. To determine the concentration of radioactivity (in cpm/ml), two 1.0 ml aliquots of the blood plasma, dialysate and peritoneal lavage samples were placed in a multichannel gamma spectrometer (1282 CompuGamma CS, LKB Wallac-Pharmacia, Turku, Finland) with appropriate window settings and background subtraction. Six 1.0 ml aliquots of the 251-albumin solution instilled at t = 0 hour were also counted. To ensure that the measured radioactivity in any sample was proteinassociated, a second set of aliquots was assayed after precipatation with 10% TCA. Free or non-protein associated 1251 amounted to less than 1% of the total radioactivity in any sample.
The blood plasma volume was determined for each sheep six hours after the infusion of Dianeal® using dilution of Evan's blue dye. The average blood plasma volume was 51.3 3.0 mI/kg.
Estimation of peritoneal volumes
To estimate the volume in the peritoneal cavity at t = 6 hours after much of the fluid was drained into a graduated cylinder, a dilution of a radioactive method was used as described earlier [11] . In addition, we estimated the intraperitoneal volume (IPV) at each time period, taking the loss of tracer from the peritoneal cavity into account [16] [17] [18] . IPV can be calculated from the difference in the amount of tracer infused and the amount of tracer lost from the peritoneal cavity, divided by the tracer concentration in the peritoneal cavity or:
where V0C0 is the volume (ml) and concentration of tracer (cpmlml) instilled at the beginning of the period being monitored, TDR is the fluid loss rate (ml/hr) based on tracer disappearance, Cgeo is the geometric mean of the initial and final tracer concentrations in the peritoneal cavity (cpmlml), VsC is the product of the volume and concentration of samples taken from the peritoneal cavity and C is the concentration of radioactivity in the peritoneal cavity.
To calculate the IPV1 at one hour: where Cimin is the tracer concentration at one minute ,and C1 is the intraperitoneal tracer concentration at one hour. To calculate the intraperitoneal volume at two hours:
where V1C1 is the peritoneal volume and tracer concentration at one hour and C2 is the intraperitoneal tracer concentration at two hours. IVP at three to six hours was calculated similarly. TDR is the fluid loss rate estimated from tracer disappearance from the peritoneal cavity. Fluid loss (TD) can be calculated as: (Eq. 4) where V11 and C0 represent the volume of fluid instilled and the concentration of radioactivity in the peritoneal cavity at t = 0 hours, V6 and C6 are the volumes and concentrations of tracer in the peritoneal cavity at the end of the experiment (six hr), and Cgeo is the geometric mean of the initial and final peritoneal tracer concentration. The fluid loss rate based on tracer disappearance was calculated as TD/6. Fluid loss (TD) could also be estimated for each hour by substituting the appropriate volumes and concentrations of tracer at the beginning and end of each period under investigation. To make these calculations we used intraperitoneal volumes estimated as described in equations I to 3.
Once the intraperitoneal volumes at each hour were calculated, the net ultrafiltration volume (NUF) could be determined as the difference between the volume in the peritoneal cavity at each hour and the infused volume. A theoretical intraperitoneal volume (tIPV) that represents the volume that entered the peritoneal cavity including an estimate of that fluid lost from the cavity can be calculated as: (Eq. 5) where SV is the volume lost to sampling. The transcapillary ultrafiltration (TCUF) can be estimated as tIPV -V0 (estimate of volume movement into peritoneal cavity without fluid loss).
Calculation of lymph flow rates based on the appearance of intraperitoneally administered tracer in the blood
Based on principles of mass balance, Flessner, Dedrick and Reynolds [19] have estimated lymph flow rates from the peritoneal cavity following the infusion of an hypertonic solution as:
where L. represents the lymph flow rate (ml/hr) from the peritoneal cavity, C(ti) represents the concentration of tracer in the peritoneal cavity at the beginning of the monitoring period, VB represents the total plasma volume (ml) and Cfl(f) represents the concentration of radioactivity (in cpm/ml) in the plasma volume at the end of the monitoring period. The radioactivity in blood is cumulative. As a consequence, in order to calculate the amount of tracer in blood at a given time, the cpm/ml in the previously collected sample was subtracted. The blood volume in each animal was estimated at the end of the experiment. We used an Evan's blue dye dilution technique. K. is the coefficient of elimination of 1251-HSA from the plasma. We have no evidence that ICOU is affected by any of the procedures used in this study and therefore have assumed that it is constant. Based on previous experiments from our laboratory, K = 0.033/hr in sheep. K5 is the slope of the peritoneal tracer concentration curve. We calculated K1 in each sheep between 0 and 6 hours and between each of the one hour periods depending on the calculation in question.
Analysis of data
The data were assessed with analysis of variance, Wilcoxon two-sample test or I-test as appropriate. P < 0.05 was significant.
Results
The concentration and recovery of 1251-albumin in the peritoneal cavity are illustrated in Figure 1 . Tracer concentration in the peritoneal cavity (expressed as a percent of the instillate concentration) declined as fluid moved into the cavity from the blood due to the osmotic gradient ( Fig. 1A ). Significantly greater dilution of the tracer was observed in the phosphatidylcholine-treated sheep suggesting that more fluid entered the peritoneal cavity in this group. Figure lB illustrates the recovery of tracer at each time in the peritoneal cavity expressed as a percent of the injected dose. Slightly more tracer left the cavity in the control animals; however, these differences were not significant.
Phosphatidylcholine enhanced net ultrafiltration (NUF) at all time points (Fig. 2 ). The data in Figure 2 employ the intraperitoneal volumes calculated as described in equations 1 to 3. In addition, NUF was calculated at the end of the experiment (6 hrs) using the volume drained from the cavity with an estimate of the undrained volume based on a dilution of tracer method. NUF calculated with the latter method rose to 30.3 3.8 ml/kg in the phosphatidylcholine group and to 12.2 2.1 mI/kg in the control animals ( Table 1 ). The six hour values calculated either way agreed closely.
Fluid loss, estimated from the disappearance of tracer from the peritoneal cavity increased over time in both groups of animals ( Fig. 3 ). While the fluid loss in the phosphatidylcholine group was less, this difference was not significant. We also calculated an average fluid loss rate using the volumes drained from the cavity at six hours with an estimate of the undrained volume employing a dilution of tracer method. Fluid loss averaged 2.3 0.2 ml hr' kg in the phosphatidylcholine-treated animals and 2.6 0.2 ml hiT' kg in the controls. The cumulative fluid loss over six hours amounted to 15.8 1.6 ml/kg and 16.8 1.7 mI/kg in the phosphatidylcholine and control groups, respectively ( Table 1) .
The blood recovery of '251-albumin expressed as a percentage of injected dose is illustrated in Figure 4 . The recovery of tracer in blood was significantly less in the phosphatidylcholine group. These values provided the basis of the lymph volume estimates which are shown in Figure 5 and, as predicted from the recovery data, the lymph volume drained from the peritoneal cavity was significantly impaired by phosphatidylcholine. The volumes removed by lymphatics were relatively constant in the phosphatidylcholine-treated sheep (ranging between 0.8 and 1.0 mI/kg), whereas volumes drained in the controls increased from 1.3 to 2.0 mI/kg by three hours and then fell to 1.5 ml/kg at the end of the experiment. The cumulative amount of liquid drained by lymphat- phosphatidylcholine-treated animals. A 2 factor ANOVA revealed that in (A), the percent instillate concentration was significantly different in the treated and non-treated animals. There were no significant differences in the tracer recoveries in the two groups (B).
ics was estimated as 5.5 1.1 ml/kg and 10.3 1.0 ml/kg in the phosphatidylcholine-treated and control sheep, respectively. The average lymph flow rates over six hours were calculated to be 0.9 0.2 ml hiT' kg' in the phosphatidylcholine group and 1.7 0.1 ml hiT' kgt in the controls. Table 1 illustrates a summary of the volume data. At six hours, the calculated intraperitoneal volumes (equations 1 to 3) were 81.0 3.8 ml/kg and 62. 1 2.2 mI/kg in the animals receiving phosphatidylcholine or dialysate alone. These values agree closely with those estimated from the volumes drained from the cavity at six hours and an estimate of the undrained volume employing a dilution of tracer method. Using the latter method volumes were Abbreviations are: V0, instilled volume; IVP, calculated intraperitoneal volume including correction for sampling; NUF, net ultrafiltration; TD, cumulative fluid loss calculated from tracer disappearance over six hours; Lpc, cumulative lymph volume removed based on tracer recovery in blood over six hours; tIVP, theoretical intraperitoneal volume calculated as IPV + TD; TCUF, transcapillaiy ultrafiltration calculated as tIPV -V0.
Groups are significantly different 81.3 3.9 mI/kg and 62.4 2.2 mI/kg in the phosphatidyicholine and controls, respectively. In both cases, IPV was significantly greater in the phosphatidyicholine-treated animals.
The theoretical intraperitoneal volumes (tIPV) (that is, the estimated volumes in the absence of fluid loss) were also significantly greater in the phosphatidyicholine group (94.6 3.6 vs. 77,5 1.8 mi/kg in the controls). Calculations of the transcapillary ultrafiltration volumes (TCUF) suggested that phosphatidyicholine facilitated the movement of fluid from the bloodstream into the peritoneal cavity. TCUF in the animals receiving phosphatidyicholine was estimated to be 43. 8 3.4 ml/kg, whereas in the control sheep it was 27.6 1.5 mI/kg. These values were significantly different. Table 2 illustrates the total tracer recovery data for these 
Discussion
Several pharmacologic agents have been added to dialysis solution in the hopes that they will enhance ultrafiltration. These include the cholinergic agents neostigmine [20, 21] and phosphatidylcholine [5-7, 22, 23] . One of the most promising agents is phosphatidylcholine. In 1985, Grahame et al [1] detected the presence of surface active material (phospholipid) in the peritoneal effluent of CAPD patients. Other studies have since established that phosphatidyicholine represents 81% of the phospholipid present [4] . Phosphatidylcholine is a substrate locally produced in the peritoneal cavity and it appears to play an important role in the normal physiology of serosal cavities [24] . Several groups reported that the level of phospholipid in the dialysis effluent decreases with time on CAPD, and it is lower still in patients with poor ultrafiltration and in patients with peritonitis [2] [3] [4] . These observations led to the speculation that an improvement in the phospholipid level might be accompanied by an improvement in ultrafiltration. Recently, Krack et al [7] reported that even though premixed phosphatidylcholine dialysis solution had a slightly higher osmolality (4%) than the comparable solution without phosphatidylcholine, the effect of this agent on ultrafiltration was more than that expected from the osmolality factor alone. With the phosphatidylcholine solutions, the patient's 
a Groups are significantly different glucose load per day can be reduced to achieve equal ultrafiltration. A major advantage of phosphatidyicholine is that it appears to increase ultrafiltration without the potential deleterious effects associated with dextrose-based dialysis solutions of increasing 0.4 osmolality.
Reports on the clinical use of phosphatidylcholine in peritoneal dialysis patients have yielded conflicting results [24] . Several
-T
investigators demonstrated that administration of phosphatidyl-0 1 2 3 4 5 6 choline either intraperitoneally, intravenously or orally, improved peritoneal ultrafiltration [5] [6] [7] . In contrast, other groups claimed Time, hours that phosphatidylcholine had no effect on ultrafiltration [22, 23] . Different phosphatidylcholine preparations and the inevitable clinical variables in each of the patients make interpretations of these results difficult. To complicate matters, the administration of phosphatidylcholine causes discomfort in some patients [22] , raising the possibility of undesirable side effects. Gagnon et al [25] tested the toxicity of phosphatidyicholine and concluded that phosphatidylcholine was toxic for peritoneal cells when combined with dialysis solution. Breborowicz et al [26] demonstrated that phosphatidylcholine had toxic effects on mesothelial cells in tissue culture.
Clearly, the use of phosphatidylcholine in dialysis requires further study given its potential benefit to ultrafiltration. Two theories have been advanced to explain how phosphatidylcholine may increase ultrafiltration under some circumstances, It may facilitate the movement of water and solutes from the vascular space into the peritoneal cavity or, it may act by reducing lymphatic drainage.
In the experiments reported here, phosphatidylcholine affected both the movement of vascular fluid into the cavity and the removal of liquid by lymphatics. In terms of ultrafiltration, some of phosphatidylcholine's effect may be due to the greater osmolality of the solution relative to the control Dianeala solution. However, one might predict that this effect is small since the osmolality of the two solutions is very close (510 vs. 480 to 490 mOsm/liter). Calculations of NUF and TCUF in the sheep experiments indicate significant increases in fluid movement into the peritoneal cavity with phosphatidylcholine and it appears unlikely that this effect is due to osmolality alone. Phosphatidyicholine, like phospholipid in lung, has surfactant properties and can reduce surface tension. Rat mesothelium has an almost equal capacity as rat lung for the synthesis of phosphatidylcholine [27] . Breborowicz et at [8] hypothesized that part of the action of phosphatidyicholine may relate to its charge effect. The positively charged choline may bind to the negatively charged mesothelial surface. Leak [28] demonstrated that a high density of anionic sites exists on the surface of the intercellular clefts of subdiaphragmatic mesothelium and lymphatic endothelium.
Phosphatidyicholine may form a water repellent surface which removes water from the intervillar spaces and reduces the thickness of the unstirred layers of fluid on the surface of the mesothelium. This may facilitate the movement of solutes from the vascular to the mesothelial side of the membrane. On the other hand, the hydrophobic fatty acid tails of the phosphatidylcholine facing the serous cavity may impair the movement of water from the mesothelial to the vascular side of the peritoneal membrane.
Mactier et at [9, 20] suggested that phosphatidyicholine increased ultrafiltration by reducing lymphatic drainage rather than by increasing transcapiliary flow. Their experiments in rats demonstrated that there was little uptake of Indian ink by the peritoneal lymphatics when phosphatidylcholine was injected into the peritoneal cavity. Similarly, in humans phosphatidylchoiine enhanced ultrafiltration and this effect was attributed to suppression of lymphatic drainage [5] . This agent may decrease peritoneal lymphatic drainage by reducing the patency of the subdiaphragmatic stomata.
Our work also demonstrated that phosphatidyicholine inhibited lymph flow (approximately 50%). However, this effect may not be the major contributor to the enhanced NUF in the phosphatidyicholine-treated animals, One would predict that a depressed lymph flow would be reflected by a reduction of the fluid loss over the course of the experiment. We did observe a slight reduction in fluid loss in the phosphatidyicholine-treated sheep, but these differences were not significant. Based on the data illustrated in Table 1 , total fluid loss in the phosphatidylcholine group was reduced by 1.0 mI/kg while the loss through lymphatics was suppressed by 4.8 mI/kg.
Since total fluid loss was much less affected by phosphatidylcholine than lymph drainage, one might speculate that the loss of liquid via routes other than the lymphatics may have increased to keep total fluid losses at roughly the same level. Perhaps more tracer moved from the peritoneal cavity into the tissues surrounding the cavity following the administration of phosphatidyicholine.
The importance of this phenomenon in estimating lymph flow rates has been emphasized by Flessner and colleagues [29, 30] .
In our experiments, tracer depostion could be due to the greater intraperitoneal pressures that one expects would occur in the phosphatidyicholine-treated animals due to the increase in intraperitoneal volumes. In the studies reported here, intraperitoneal volumes at six hours averaged 2139 161 ml in the phosphatidyicholine group and 1830 127 ml in the controls, a difference of 309 ml. In a previous report we published the pressure-volume relationships in the sheep peritoneal cavity [13] . Based on an increase of 309 ml in the phosphatidyicholine-treated sheep, we estimate that intraperitoneal pressures would increase approximately 1 cm H2O. Flessner, Parker and Sieber [31] reported that intraperitoneal pressures affected fluid loss rates but not lymph flow rates. Whether a 1 cm H20 intraperitoneal pressure increase is enough to account for the greater nonlymphatic fluid loss in our phosphatidyicholine-treated animals is not known.
If fluid loss by a non-lymphatic route was increased such that the total liquid removed from the peritoneal cavity remained approximately the same, the total tracer recovery data illustrated in Table 2 would be expected to reflect greater tracer loss (that is, unaccounted for tracer) in the phosphatidylcholine-treated animals. The total recovery of 1251-albumin in the control and treated animals was 91.8 and 88.0, respectively. This 3.8% difference in recoveries was not significant (given the relatively small number of animals used in this study). However, one might argue that a loss of 3.8% of the instilled tracer in the tissues surrounding the cavity could account for the volume differences between estimates of fluid loss and lymph drainage.
The fluid loss (estimated from tracer disappearance was 16.8 mi/kg in the controls. Lymph drainage accounted for 10.3 mI/kg. In the phosphatidyichoiine-treated sheep, fluid loss was 15.8 mi/kg of which 5.5 mi/kg was removed by lymphatics. Therefore, the difference between the total fluid lost and the lymph drainage amounted to 6.5 mi/kg in the controls versus 10.3 mi/kg in the phosphatidyichoiine-treated sheep. These values may represent the volumes removed from the peritoneai cavity by a nonlymphatic route. Subtracting 6.5 from 10.3 yieids 3.8 mi/kg. If this reasoning is correct, the 3.8 mI/kg represents the increased volume that would have to leave the peritoneai cavity via a non-iymphatic route in the phosphatidyicholine group in order to keep the total fluid lost from the cavity roughly constant in the two groups. Based on equation 4 the hypothetical amount of tracer that would have to be removed from the peritoneal cavity can be caiculated to account for a 3.8 mi/kg greater volume loss in the treated animals, An estimated 5.3% of the injected radioactivity must be lost from the peritoneai cavity to account for the 3.8 mi/kg. A 3.8% difference was observed in total recoveries in the two groups. These numbers are close enough to suggest the possibility that phosphatidyichoiine treatment resulted in greater deposition of 1251-albumin in the tissues surrounding the peritoneai cavity.
At this point, some comment should be made concerning the method used to calculate lymph drainage of the peritoneal cavity. This remains a contentious issue. Several investigators estimate lymph drainage as the disappearance rate of a lymph flow marker from the peritoneai cavity and have reported that phosphatidylcholine depressed lymph drainage of the peritoneal cavity, [5, 9, 20] . Several groups compared lymph drainage using this method with that empioyed in this study, that is, the appearance of intraperitoneaiiy administered tracer in the blood [14, 17, 31] . Lymph flows estimated from the appearance of tracer in the bloodstream were always less than those estimated from the disappearance of the tracer moiecuie. This difference may be due to the movement of liquid and the lymph flow marker into the tissues surrounding the peritoneai cavity with the tracer and fluid reentering the blood at different rates [reviewed in 32].
How would the conclusions we have made above differ if we were to use the tracer disappearance technique to estimate lymph drainage? We wouid assume that au fluid lost from the peritoneal cavity escaped by lymphatics. Based on this approach, the data would suggest that phosphatidyicholine had little impact on lymphatic drainage and we would conciude that its greatest effect was to promote transcapiiiary ultrafiltration. Therefore, despite the fact that these methods of calculation provide a different perspective on the role of lymphatics, the major conclusion of the study is the same.
In humans [5] and rats [9, 20] , phosphatidylcholine significantly reduced tracer disappearance from the peritoneai cavity. We can only assume that species differences exist since the tracer disappearance in sheep was not significantiy affected by phosphatidylchoiine.
In summary, one must be cautious when extranoiatine studies in sheep to humans. One major difference between the animal model and peritoneal dialysis patients is that the animals have normal kidney function and it is not clear how kidney disease may affect lymphatic drainage of the peritoneal cavity. Nonetheless, in physiological terms, the addition of phosphatidyicholine to dialysate significantly improved net ultrafiltration. Phosphatidylcholine suppressed lymph drainage of the peritoneal cavity, but this effect did not appear to contribute significantly to peritoneal volume dynamics since the total fluid loss was very similar in the phosphatidyicholine-treated and non-treated animals. The data support the hypothesis that the main effect of phosphatidyicholine is to facilitate the movement of liquid from the blood into the peritoneal cavity.
